Oncology Venture receives response from the FDA to the IND-application and proposed pivotal study for LiPlaCis

Ads

You May Also Like

CohBar Announces the Appointment of Dr. John Amatruda to its Board

MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an ...

Interpace Diagnostics Announces Expansion of LabCorp National Agreement

PARSIPPANY, N.J., March 20, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” ...